Shares of Immunogen Inc.
blasted 121.2% higher on heavy volume toward a five-year high in premarket trading Wednesday, after the biopharmaceutical company revealed positive data from a late-stage trial of its treatment for ovarian cancer. Trading volume spiked up to 12.2 million shares, compared with the full-day average of about 3.5 million shares. The company said its Elahere demonstrated a “significant and clinically meaningful” survival benefit and progression-free survival compared with chemotherapy.
blasted 121.2% higher on heavy volume toward a five-year high in premarket trading Wednesday, after the biopharmaceutical company revealed positive data from a late-stage trial of its treatment for ovarian cancer. Trading volume spiked up to 12.2 million shares, compared with the full-day average of about 3.5 million shares. The company said its Elahere demonstrated a “significant and clinically meaningful” survival benefit and progression-free survival compared with chemotherapy.